QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Vol. 17, Issue 7, 2869-2881, July 2006

This Article Abstract Full Text (PDF) All Versions of this Article: E05-11-1001v1 17/7/2869    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Even-Faitelson, L. Articles by Ravid, S. Search for Related Content PubMed PubMed Citation Articles by Even-Faitelson, L. Articles by Ravid, S.

PAK1 and aPKC Regulate Myosin II-B Phosphorylation: A Novel Signaling Pathway Regulating Filament Assembly

Department of Biochemistry, Institute of Medical Sciences, Faculty of Medicine, The Hebrew University, Jerusalem 91120, Israel

Submitted November 2, 2005; Revised March 28, 2006; Accepted April 5, 2006
Monitoring Editor: Martin A. Schwartz

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Many signaling pathways regulate the function of the cellular cytoskeleton. Yet we know very little about the proteins involved in the cross-talk between the signaling and the cytoskeletal systems. Here we show that myosin II-B, an important cytoskeletal protein, resides in a complex with p21-activated kinase 1 (PAK1) and atypical protein kinase C (PKC) zeta (aPKC) and that the interaction between these proteins is EGF-dependent. We further show that PAK1 is involved in aPKC phosphorylation and that aPKC phosphorylates myosin II-B directly on a specific serine residue in an EGF-dependent manner. This latter phosphorylation is specific to isoform B of myosin II, and it leads to slower filament assembly of myosin II-B. Furthermore, a decrease in aPKC expression in the cells alters myosin II-B cellular organization. Our finding of a new signaling pathway involving PAK1, aPKC, and myosin II-B, which is implicated in myosin II-B filament assembly and cellular organization, provides an important link between the signaling system and cytoskeletal dynamics.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The cytoskeleton consists of a complex network of proteins responsible for many cellular processes such as adhesion, cytokinesis, and cell motility. To be able to perform these functions the cytoskeleton must be highly dynamic and reorganize rapidly in specific regions of the cell in response to extracellular signals. Nonmuscle myosin II is an important part of this complex cyotoskeletal network and plays a major role in its functions.

Myosin II is a hexamer composed of two heavy chains of 200 kDa and two pairs of light chains (MLCs). Whereas the regulation of MLC has been extensively investigated, little is known about the regulation and phosphorylation of the myosin heavy chains. In vertebrates, there are at least three nonmuscle myosin II heavy chain (NMHC) genes that encode separate isoforms of the heavy chain: NMHC II-A, NMHC II-B, and NMHC II-C (Katsuragawa et al., 1989; Kawamoto and Adelstein, 1991; Berg et al., 2001; Buxton et al., 2003). These isoforms have different tissue and cellular distribution and different functions (Cheng et al., 1992; Miller et al., 1992; Maupin et al., 1994; Rochlin et al., 1995; Kelley et al., 1996; Straussman et al., 2001).

Nonmuscle myosin II needs to undergo dynamic assembly–disassembly for it to function within a cell. Murakami et al. have shown that the filament assembly–disassembly of myosin II-A and myosin II-B are separately regulated. The filament assembly of myosin II-A is regulated mainly by the binding of the protein Mts1, although recent work has show that it is also regulated by phosphorylation (Dulyaninova et al., 2005), whereas myosin II-B assembly is regulated by phosphorylation of the nonhelical C-terminal domain of NMHC II-B (Murakami et al., 1998, 2000). We have recently shown that NMHC II-B phosphorylation in response to EGF is necessary for its localization within the cell and that NMHC II-B plays a crucial role in chemotaxis (Straussman et al., 2001; Ben-Ya’acov and Ravid, 2003).

Mammalian p21-activated kinases (PAKs) have been implicated in the regulation of a number of cellular activities, including regulation of MAP kinase signaling pathways, apoptosis and the cell cycle, and cytoskeletal dynamics (Knaus and Bokoch, 1998). PAKs are effector proteins of the Rho small GTPases, Rac and Cdc-42, and this family of serine/threonine kinases comprises six members (Jaffer and Chernoff, 2002). Recently, van Leeuwen et al. (1999) have shown that PAK1 is involved in the bradykinin-dependent phosphorylation of NMHC in PC12 cells. Moreover, we have recently shown that PAK1 is involved in the regulation of myosin II-B phosphorylation, localization, and filament assembly (Even-Faitelson et al., 2005).

Another family of serine/threonine kinases, the PKCs, play a central role in many signal transduction pathways in the cell. The PKC family is divided into three main groups with different structures and different activators. The conventional PKCs, including cPKC, cPKCI, cPKCII, and cPKC, require phosphatidylserine (PS), Ca²⁺, and diacylglycerol (DAG) to activate them. Novel PKCs, including nPKC, nPKC, nPKC, and nPKC, require only PS and DAG. Finally, atypical PKCs, such as aPKC, aPKC, and aPKC, require only PS to activate them.

Among playing a role in many cell signaling pathways, PKC appears to be an important regulator in cytoskeletal function. It has been shown that PKC and cytoskeletal proteins are colocalized, treatment of cells with PKC activators causes cytoskeletal rearrangement, and PKC phosphorylates cytoskeletal proteins (Keenan and Kelleher, 1998). Various studies show that PKC is involved in regulating MLC either directly or by regulating MLC-kinase (Ikebe et al., 1985, 1987; Turbedsky et al., 1997). PKC also appears to play a role in the regulation of NMHC (Murakami et al., 1998; Straussman et al., 2001; Su and Kiehart, 2001). Furthermore, aPKC is involved in actin cytoskeletal regulation (Gomez et al., 1995, 1997; Laudanna et al., 1998; Uberall et al., 1999; Hellbert et al., 2000; Chodniewicz and Zhelev, 2003). Uberall et al. (1999) have suggested that aPKC works downstream to Rac1 in Ras-mediated rearrangement of the actin cytoskeleton. Additionally, Laudanna et al. (1998) have shown that aPKC is involved in the signaling pathway, leading to chemoattractant-triggered actin assembly, integrin-dependent adhesion, and chemotaxis of polymorphonuclear neutrophils.

The many important cellular functions of the cytoskeleton have generated intensive investigation of cellular signaling pathways influencing the cytoskeletal meshwork. Here we provide evidence for a novel signal transduction pathway that begins with the stimulation of TSU-pr1 cells with EGF and ends with the phosphorylation of NMHC II-B by aPKC, which functions downstream to PAK1. This signaling pathway is involved in the regulation of myosin II-B filament assembly and cellular organization.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Cell Line and Culture Conditions
The cell line used here was a prostate carcinoma cell line, TSU-pr1 (Iizumi et al., 1987). This cell line was derived from human prostate adenocarcinoma, metastatic to lymph node (kindly provided by Dr. Antonnino Passaniti, University of Maryland National Institute of Health, Baltimore, MD). Cells were maintained as described previously (Ben-Ya’acov and Ravid, 2003). COS-7 and HEK-293 cell lines were maintained as described previously (Rosenberg and Ravid, 2006).

Antibodies and Reagents
The following antibodies were used in this work: PAK1 (N-20), aPKC, cPKCII, Cdk7 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), HA antibodies (Roche, Basel, Switzerland), affinity-purified specific polyclonal antibodies against the C-terminal of NMHC II-B (Straussman et al., 2001; Ben-Ya’acov and Ravid, 2003) or against GFP, cPKC, nPKC, and aPKC antibodies (BD Transduction Laboratories, San Jose, CA), and PAK1 and p42-MAP Kinase (p42-MAPK) antibodies (Cell Signaling Technology, Danvers, MA). All other reagents, unless otherwise specified, were purchased from Sigma (St. Louis, MO).

Immunoprecipitation of PAK1 from TSU-pr1 Cells and In Vitro Phosphorylation
Immunoprecipitation of PAK1 from TSU-pr1 cells was carried out as described previously (Even-Faitelson et al., 2005). The IP-PAK1 was used to phosphorylate 10 µg MBP, NMHC II-A, or NMHC II-B in an in vitro activity assay described previously (Even-Faitelson et al., 2005). The samples were separated on SDS-PAGE, and the extent of phosphorylation was measured by counting the bands in a scintillation counter. The relative phosphorylation was calculated by dividing the phosphorylation level of each protein by the phosphorylation level of that same protein without EGF stimulation.

Coimmunoprecipitation, Gel Electrophoresis, and Western Blotting
Cells, 5 x 10⁵, were starved to serum as described previously (Even-Faitelson et al., 2005) and then stimulated with 7 ng ml^–1 EGF for 0, 1, or 4 min. At the indicated time points, the plated cells were washed with ice-cold phosphate-buffered saline (PBS) and then collected in 300 µl sonication buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM DTT, 2 mM EDTA, Protease Inhibitors Cocktail). Cells were then sonicated, incubated for 15 min on ice, and centrifuged at 25,000 x g for 15 min at 4°C. Supernatants were transferred to fresh tubes and rotated at 4°C for 2 h with protein A/G agarose beads (Pierce, Rockford, IL) coupled covalently to polyclonal PAK1 antibodies, affinity-purified specific polyclonal antibodies against the C-terminal of NMHC II-B, monoclonal aPKC antibodies, polyclonal Cdk7 antibodies, or beads only. Cdk7 antibodies or beads only were used as negative control for the coimmunoprecipitation experiments. The covalent coupling was performed essentially as described (Simanis and Lane, 1985). Briefly, the beads were washed twice with 0.2 M sodium borate, pH 9.0, incubated o/n at RT with 20 mM dimethyl pimelimidate dihydrochloride and then washed twice and incubated for 2 h at RT with 0.2 M ethanolamine, pH 8.0. The beads–antibody complex was then washed three times with sonication buffer and resuspended in SDS-PAGE sample buffer. For the coimmunoprecipitation of PAK1 with NMHC II-B and aPKC the cells were transiently transfected with pCMV6M-PAK1 (kindly provided by Dr. Gary M. Bokoch, The Scripps Research Institute), and the rest of the procedure was carried out as described above. Whole cell extract were prepared by lysing the same amount of cells used for immunoprecipitation with SDS-PAGE sample buffer. Only half of the amount of the total whole cell extract was loaded on each gel. Samples were separated on 10% SDS-PAGE, and Western blotting was performed using standard procedures using the same antibodies used for the immunoprecipitation and cPKCII, cPKC, nPKC, and aPKC antibodies.

NMHC II-A and NMHC II-B Tail Phosphorylation by Recombinant aPKC or GST-PAK1
Phosphorylation of NMHC II-A and NMHC II-B tails using recombinant aPKC (Sigma) was performed according to the manufacturer’s instructions. Briefly, 10 µg of NMHC II-A or NMHC II-B tail in "tail mix" (25 mM Tris-HCl, pH 7.5, 5 mM MgCl₂, 0.5 mM EGTA, 1 mM DTT, 100 µM ³²P-ATP [Amersham Pharmacia Biotech, Piscataway, NJ], and 10 µl/sample Lipid mix [prepared according to manufacturer’s instructions]) were either mixed with diluted recombinant aPKC, dilution buffer (as specified by the manufacturer) without the enzyme or with TSU-pr1 cell lysate and incubated at 30°C for 20 min. The reaction was stopped by the addition of cold 10% TCA. Samples were washed with 5% TCA, resuspended in SDS-PAGE sample buffer, and separated on 12% SDS-PAGE. Gels were stained and phosphorylation of NMHC II-A and NMHC II-B tails was determined by exposing the gels to film or by cutting the bands and counting them in a scintillation counter. To achieve the best enzyme-substrate ratio for maximum phosphorylation of NMHC II-B tail by aPKC, several quantities of substrate (0.01, 0.1, 0.5 µg) and enzyme (0.02, 0.05, 0.08 µg) were used. Phosphate incorporation (mol phosphate per mol NMHC II-B tail) was calculated according to the following formula: (cpm x nmol ATP in the reaction/total cpm)/nmol NMHC II-B tail in the reaction.

NMHC II-B tail or MBP phosphorylation by PAK1 was performed using GST-PAK1 (kindly provided by Dr. Gary M. Bokoch, The Scripps Research Institute). GST-PAK1, 1 µg, was used to phosphorylate 1 µg substrate (NMHC II-B tail or MBP) in PAK1 kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl₂, 2 mM MnCl₂, 0.2 mM DTT). The reaction was initiated by the addition of 20 µM ATP and 0.5 µCi ³²P-ATP. The reaction was stopped by the addition of 15 µl 5x SDS-PAGE sample buffer. Phosphorylation levels were determined as described above.

Expression, Immunoprecipitation, and Phosphorylation of GFP-NMHC II-B by aPKC
pEGFP-C3-NMHC II-B full length (kindly provided by Dr. R. S. Adelstein, Laboratory of Molecular Cardiology, NIH) was transfected to 60% confluent COS-7 cells on 60-mm plates using jetPEI transfection reagent (Polyplus-transfection, Strasbourg, France). Forty-eight hours after the transfection the cells were washed once with cold PBS and lysed with 400 µl modified lysis buffer for activity assay (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, 50 mM NaPPi, 100 mM NaF, 0.2% Triton X-100). The GFP-NMHC II-B was immunoprecipitated as described above using affinity-purified rabbit polyclonal GFP antibodies. The immunoprecipitates were washed twice with the modified lysis buffer for activity assay, twice with lysis buffer for activity assay (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 50 mM NaCl, 0.2% Triton X-100), and once with washing buffer (25 mM Tris-HCl, pH 7.5, 5 mM MgCl₂, 0.5 mM EGTA). The phosphorylation reaction was carried out using recombinant aPKC, essentially as described above. The samples were separated on 6% SDS-PAGE, stained with Coomassie brilliant blue, scanned, dried, and exposed to film.

aPKC Phosphorylation by Recombinant GST-PAK1
pCDNA3-HA-aPKC^WT/KD(K281R) (kindly provided by Dr. Yehiel Zick, The Weizmann Institute) or pEGFP (Clontech, San Jose, CA) control were transfected to HEK-293 cells using the calcium-phosphate transfection protocol (Chen and Okayama, 1987). After 24 h the cells were lysed with Buffer H (50 mM -glycerophosphate, pH 7.4, 1.5 mM EGTA, 1 mM EDTA, 1 mM DTT, 50 mM NaCl, 0.1 mM Na₃VO₄, 0.5% NP-40, Protease Inhibitor Cocktail), incubated on ice, and centrifuged as described above. The supernatants were incubated with Ultralink Immobilized Protein G (Pierce) bound to anti-HA antibodies for 2 h at 4°C. To remove any protein that may have coimmunoprecipitated with aPKC, the complex was washed stringently: twice with 1% NP-40 in PBS, twice with 10 mM Tris, pH 7.5, 0.5 M LiCl; once with 10 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA; and twice with PAK1 kinase buffer described above. Kinase assay was performed on the immunoprecipitates as described above for the phosphorylation of MBP/NMHC II-B tail by GST-PAK1.

In Vivo Phosphorylation of TailB-6A and TailB-7A
A 530-base pair C-terminal fragment of NMHC II-B in which 7 serine residues were mutated to alanine residues (amino acids 1922, 1935, 1937, 1938, 1939, 1941, and 1952, see Figure 6A) was restricted from pET21C vector (Novagen, San Diego, CA) using XhoI and SmaI (Fermentas, Ontario, Canada) and cloned into pEGFP-C3 (Clontech) using the same restriction sites (pEGFP-TailB7A). A site-directed mutagenesis reaction (QuikChange, Stratagene, La Jolla, CA) was carried out on the above pEGFP-TailB7A to convert back the alanine at position 1937 to serine (pEGFP-TailB6A). The mutations were verified by DNA sequencing (Center for Genomic Analysis, The Hebrew University, Jerusalem, Israel).

TSU-pr1 cells, 8 x 10⁵, were seeded on 60-mm plates, and pEGFP-TailB-6A or pEGFP-TailB-7A were transfected to the cells using jetPEI (Polyplus-transfection) 44 h before the experiment. Cells were washed twice in 2 ml prewarmed RPMI-H (Even-Faitelson et al., 2005) without phosphate and then incubated for 2 h with 3 ml RPMI-H containing 80 µCi ³²P orthophosphate (Amersham Pharmacia Biotech). After 2 h half the plates were treated with 10 µM cell permeable aPKC inhibitor (myristoylated pseudosubstrate, Biosource, Camarillo, CA) for 50 min (Etienne-Manneville and Hall, 2003). Next, the plates were either not stimulated or stimulated for 1 min with EGF and then washed with PBS and lysed with 1x RIPA (50 mM Tris-HCl, pH 7.5, 1% NP-40, 0.5% deoxycholic acid, 50 mM sodium pyrophosphate, 100 mM sodium fluoride, and protease inhibitor mix). Lysates were incubated on ice and centrifuged as described above, and the supernatants were incubated overnight with protein A-agarose (Pierce) that were preincubated and cross-linked to NMHC II-B antibodies described above. After incubation, the complex was washed three times with 1x RIPA and loaded on 10% SDS-PAGE. The gels were stained with Coomassie, scanned, dried, and exposed to an autoradiogram. The amount of the proteins and their phosphorylation levels were quantified using Fujifilm ImageGauge Ver. 3.4 (Fuji, Tokyo, Japan). To standardize the phosphorylation level to protein quantity, the value of phosphorylation was divided by the total protein value. Then, the percent of phosphorylated protein after treatment with the inhibitor was calculated by dividing the standardized phosphorylation of the inhibitor treated sample by the standardized phosphorylation of the untreated sample at the same time point. To calculate the relative phosphorylation of EGF-stimulated Tail-6A compared with unstimulated Tail-6A, the standardized phosphorylation of the EGF-stimulated sample in each experiment was divided by the value of the standardized phosphorylation of the unstimulated sample in the same experiment. The average relative phosphorylation was calculated from the results of three separate experiments.

siRNA of PAK1 or aPKC and In Vivo Phosphorylation of aPKC or NMHC II-B, Respectively
siRNA of PAK1 was carried out using SignalSilence PAK1 siRNA (Cell Signaling Technology). For a control, SignalSilence nonspecific fluorescein-conjugated siRNA was used (Cell Signaling Technology). siRNA of aPKC was carried out using Dharmacon’s SMARTpool siRNA designated to target aPKC (Dharmacon, Lafayette, CO). As a control, siCONTROL NonTargeting siRNA Pool was used (Dharmacon). Transfection of the siRNA to the cells was carried out using TransIT-TKO transfection reagent according to the manufacturer’s instructions (Mirus, Madison, WI). Briefly, TSU-pr1 cells were seeded on 60-mm plates to reach 70% confluence on the day of transfection and then transfected with 100 nM PAK1 siRNA, 50 nM aPKC SMARTpool siRNA, or 25 nM control siRNA. Cells were incubated for 48 h before performing the experiment. To monitor transfection efficiency, on the day of the experiment the control siRNA cells were observed using a fluorescence microscope.

The in vivo phosphorylation assay was carried out essentially as described above for the phosphorylation of TailB-6A and TailB-7A, but with a few modifications. The siRNA-treated cells were washed and incubated with RPMI-H (Even-Faitelson et al., 2005) without phosphate containing 80 µCi ³²P orthophosphate and then incubated as described above. The EGF-stimulated and unstimulated cells were then lysed, as described above. Ten percent of the cleared lysate was used for testing PAK1 or aPKC siRNA efficiency using Western blot analysis, and the rest of the lysate was used for immunoprecipitation of aPKC or NMHC II-B. The immunoprecipitates and lysates were separated on 10% SDS-PAGE, or 6% for NMHC II-B. The lysates were transferred to nitrocellulose membrane and Western blotting was performed as described above using PAK1 antibodies (Santa Cruz or Cell Signaling Technology) and p42-MAPK antibodies (Cell Signaling Technology) for loading control, or aPKC antibodies (Santa Cruz) and p42-MAPK antibodies. The gel with the aPKC immunoprecipitates was silver-stained using silverSNAP kit (Pierce) and then scanned, dried, and exposed to film. The gel with the NMHC II-B immunoprecipitates was stained using Coomassie brilliant blue, scanned, dried, and exposed to film. The quantification was carried out as described above. The decrease in PAK1 or aPKC expression was calculated by dividing the amount of PAK1 or aPKC with the amount of p42-MAPK and comparing between the lysates from cells that were transfected with PAK1 siRNA or aPKC SMARTpool siRNA and lysates from cells that were transfected with control siRNA. Standardization of the phosphorylation level of aPKC or NMHC II-B to the total aPKC or NMHC II-B immunoprecipitated was done as described above. In each experiment the phosphorylation level of aPKC or NMHC II-B of each sample was divided by the value of phosphorylated aPKC or NMHC II-B in the control siRNA sample, thus leading to a relative phosphorylation value.

Protein Purification, Critical Concentration, and Solubility Assay
Expression and purification of myosin proteins was carried out essentially as described by (McNally et al., 1991) with a few modifications. Briefly, Escherichia coli strain BL-21 containing the pET21c-NMHC II-B rod plasmid, which encodes for 630 amino acids derived from the C-terminal of NMHC II-B (hereafter referred to as NMHC II-B rod), wild-type, or S1937D mutant, were grown to OD₆₀₀ = 0.6 and then induced with 0.5 mM IPTG for 2 h. Bacteria pellets were lysed with lysis buffer (50 mM Tris-HCl, pH-7.5, 0.8 M NaCl, 10 mM EDTA, 10 mM EGTA, 1 mM DTT, 1 mg/ml lysozyme, and 0.5 mM phenylmethylsulfonyl fluoride) and sonicated. Sonicates were centrifuged, and the DNA was precipitated from the supernatant with 10% polyethylenimine (Burgess, 1991), centrifuged again, and then boiled to denature all proteins except for the -helical coiled NMHC II-B rod. The mixture was then centrifuged at 100,000 x g, and the NMHC II-B rod was precipitated from the supernatant using ammonium sulfate. The ammonium sulfate pellet was solubilized in Buffer G (20 mM Tris-HCl, pH 7.5, 600 mM NaCl, 5 mM EDTA, and 1 mM DTT).

To determine the critical concentration, the proteins were diluted to 15, 25, 50, 100, or 250 µg/ml in Buffer G (20 mM Tris-HCl, pH 7.5, 600 mM NaCl, 5 mM EDTA, and 1 mM DTT). Eighty microliters of each protein concentration were dialyzed for 4 h in 150 mM dialysis buffer (10 mM phosphate buffer, 2 mM MgCl₂, and 150 mM NaCl), centrifuged in a TL-100 ultracentrifuge (Beckman Coulter, Fullerton, CA) at 100,000 x g, for 1 h at 4°C, and the supernatant and pellet were separated. Twenty microliters of the supernatant and the pellet that was solubilized in 80 µl Buffer G were loaded on 10% SDS-PAGE. The gels were stained with Coomassie brilliant blue, scanned, and quantified using Fujifilm image analyzer LAS-1000plus and the densitometry program Fujifilm ImageGauge Ver. 3.4.

Solubility assays were performed similarly. The proteins were diluted in Buffer G to a concentration of 0.5 mg/ml and dialyzed in 150 mM dialysis buffer. An 80-µl sample was taken at 1, 1.5, 2, 3, and 4 h after the beginning of the dialysis and centrifuged as described above. Forty microliters of the supernatant were diluted in 360 µl Buffer G, and the pellet was solubilized in 800 µl Buffer G. The remaining procedure was as described above.

Microscopy
Indirect immunofluorescent staining was performed as described (Ben-Ya’acov and Ravid, 2003). Cells were stimulated with 7 ng ml^–1 of EGF for 0, 1, or 4 min at RT. Cells were fixed, permeabilized, and stained using polyclonal antibody specific for the N-terminal domain of NMHC II-B (kindly provided by R. S. Adelstein) and monoclonal antibody for aPKC. Immunofluorescence was achieved using goat anti-rabbit IgG conjugated to Cy5 (Jackson ImmunoResearch, West Grove, PA) and goat anti-mouse Alexa 448 (Invitrogen-Molecular Probes, Carlsbad, CA) as secondary antibodies. To quantify the number of cells that show colocalization at each time point of EGF stimulation, several random fields of cells were counted in three individual experiments (average number of cells counted at each time point: n = 180). The cells were classified as showing colocalization or not showing colocalization and the results are presented as the percentage of cells showing colocalization out of the total number of cells counted. For indirect immunofluorescent staining of cells treated with aPKC or control siRNA, 48 h after transfection with the siRNA the above procedure was performed. Quantification of cells that show cortical localization of NMHC II-B after EGF stimulation was performed by counting an average of 200 cells, transfected either with aPKC siRNA or control siRNA, from 10 random fields.

Mass Spectrometry
NMHC II-B tail, 5 µg, was phosphorylated using 2.5 µg recombinant aPKC, as described above, except for the ATP concentration in the mixture, which was 250 µM instead of 100 µM, and ³²P-ATP was not present. The sample was separated on 12% SDS-PAGE together with nonphosphorylated NMHC II-B tail, for comparison, and stained with Coomassie brilliant blue. The phosphorylated and unphosphorylated NMHC II-B tail bands were excised from the gel, reduced, alkylated, and digested in-gel using sequencing-grade trypsin (Promega, Madison, WI) as described elsewhere (Pandey et al., 2000). Desalting of the peptide mixture was performed using ZipTip C₁₈ column (Millipore, Billerica, MA), and the peptides were eluted using 80% acetonitrile, 1% formic acid. The eluted peptides were directly injected by spraying capillaries (Protana, Toronto, Canada) to a Q-TOF II mass spectrometer (Micromass, Toronto, Canada) equipped with a nanoelectrospray source. MS and MS/MS spectra were measured using 1200 V capillary voltage, and the MS/MS collision energy was 20–45 V.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
PAK1 Is Involved in NMHC II-B Phosphorylation, But Does Not Phosphorylate It Directly
We have recently shown that PAK1 is involved in EGF-dependent phosphorylation of NMHC II-B but not in NMHC II-A phosphorylation (Even-Faitelson et al., 2005). Figure 1A shows that stimulation of cells with EGF leads to increased phosphorylation activity of immunoprecipitated PAK1 (IP-PAK1) on NMHC II-B C-terminal fragment (NMHC II-B tail) and on myelin basic protein (MBP) positive control in comparison to IP-PAK1 from unstimulated cells. On the other hand, IP-PAK1 did not show increased phosphorylation on NMHC II-A C-terminal fragment (NMHC II-A tail) in response to EGF stimulation.

View larger version (30K): [in this window] [in a new window]   Figure 1. PAK1 is involved in NMHC II-B phosphorylation, but does not phosphorylate it directly. (A) IP-PAK1 phosphorylates NMHC II-B and MBP, but not NMHC II-A, in an EGF-dependent manner. Unstimulated TSU-pr1 cells or cells stimulated with EGF for 1 min were lysed, and PAK1 was immunoprecipitated and used in an in vitro activity assay with NMHC II-A tail, NMHC II-B tail, or MBP as substrates. The samples were separated on SDS-PAGE, and bands were excised and counted in scintillation counter. Results are shown as mean ± SD of three separate experiments. (B) Recombinant GST-PAK1 does not phosphorylate NMHC II-B directly. GST-PAK1 was used in an in vitro activity assay with MBP and NMHC II-B as substrates. The samples were separated on SDS-PAGE, stained with Coomassie, and exposed to autoradiography. The results are representative of three experiments. (C) aPKC coimmunoprecipitates with PAK1. The expression of the different PKC isoforms in TSU-pr1 cells was determined by resolving cell extracts on SDS-PAGE followed by Western blot analysis with antibodies specific for the different PKC isoforms. The association between PAK1 and PKC isoforms was determined by immunoprecipitating PAK1 from TSU-pr1 lysates and subjecting it to Western blot analysis with the appropriate antibodies. See Materials and Methods for details for this and all other figures.

aPKC Is Present in the IP-PAK1 Complex That Phosphorylates NMHC II-B
The next step was to search for the protein(s) that interact with PAK1 and are responsible for the direct phosphorylation of NMHC II-B in response to EGF stimulation. Previous studies by us and by other groups confirmed that PKC is involved in NMHC phosphorylation (Conti et al., 1991; Murakami et al., 1994; Murakami et al., 1995, 2000; Straussman et al., 2001; Su and Kiehart, 2001), and we found that TSU-pr1 cells express the PKC isoforms: cPKCII, cPKC, nPKC, and aPKC (Straussman et al., 2001). We therefore investigated which of these PKCs coimmunoprecipitate with PAK1.

We immunoprecipitated PAK1 from TSU-pr1 cell lysates and subjected it to Western blot analysis using specific antibodies against the PKC isoforms. The same amount of cells was used for each immunoprecipitation and, as shown in Figure 1C, only aPKC coimmunoprecipitated with PAK1. We went on to examine the involvement of aPKC in the regulation of NMHC II-B.

PAK1, aPKC, and NMHC II-B Are All Found in One Complex In Vivo
The next step was to show a direct link between PAK1, aPKC, and NMHC II-B. To determine whether PAK1, aPKC, and NMHC II-B interact in vivo, we immunoprecipitated each of these proteins and checked if they coimmunoprecipitated with each other by subjecting them to Western blot analysis as described in Materials and Methods. As shown in Figure 2A, immunoprecipitated NMHC II-B subjected to Western blot analysis with aPKC-specific antibody clearly indicates that aPKC coimmunoprecipitates with NMHC II-B. Moreover, aPKC and PAK1 were immunoprecipitated and subjected to Western blot analysis using NMHC II-B–specific antibody and indeed, as shown in Figure 2A, NMHC II-B coimmunoprecipitated with both aPKC and PAK1. Furthermore, in order to see that the interactions are specific, we performed the reciprocal experiment. Figure 2A clearly shows that PAK1 coimmunoprecipitates with both NMHC II-B and aPKC. The interactions between aPKC, NMHC II-B, and PAK1 are specific because they barely immunoprecipitated with the negative controls. Together these results strongly indicate that PAK1, aPKC, and NMHC II-B all reside in one complex in vivo.

View larger version (23K): [in this window] [in a new window]   Figure 2. PAK1, aPKC, and NMHC II-B are all found in one complex and the interaction between aPKC and NMHC II-B is EGF-dependent. (A) Representative Western blots of coimmunoprecipitations of NMHC II-B, aPKC, and PAK1 from TSU-pr1 cells stimulated with EGF for 1 min. Immunoprecipitation was carried out using aPKC, PAK1, and NMHC II-B antibodies (IP-aPKC, IP-PAK1, and IP-NMHC II-B, respectively). Cdk7 antibodies or beads only were used as negative controls (Control). The immunoprecipitations were separated on SDS-PAGE, and Western blot was carried out using the antibodies indicated on the left. The amount of protein in the whole cell extract (WCE) represents 50% of the total protein in the lysates used for the immunoprecipitation. (B) aPKC was immunoprecipitated from TSU-pr1 cell lysates that were stimulated with EGF for 0, 1, or 4 min and subjected to Western blot analysis using aPKC antibodies (left blot). The blot was then probed with anti-NMHC II-B antibody (right blot). Relative molecular masses (in thousands) are given to the left of the gels. The Western blot is representative of three experiments. (C) Quantification of three experiments as shown in B, presented as the amount of NMHC II-B that coimmunoprecipitates with aPKC at each time point after EGF stimulation, relative to the amount of NMHC II-B that coimmunoprecipitates with aPKC in unstimulated cells (mean ± SD). The amount of immunoprecipitated NMHC II-B at each time point was standardized by dividing its value with the value of the immunoprecipitated aPKC of that same time point.

View larger version (35K): [in this window] [in a new window]   Figure 3. EGF-dependent localization of NMHC II-B and aPKC in TSU-pr1 cells. (A) Immunofluorescence staining of aPKC (top panels, green) and NMHC II-B (middle panels, red) in TSU-pr1 cells stimulated with EGF for 0, 1, or 4 min. Areas of colocalization are yellow and are indicated with arrowheads (Merge). Bar, 10 µm. (B) Quantification of the number of cells that exhibit colocalization between NMHC II-B and aPKC at each time point after EGF stimulation. The results are presented as mean ± SD of the percentage of cells that show colocalization out of the total number of random cells counted in three independent experiments (average total cells counted for each time point: n = 180).

Furthermore, our results indicate that aPKC’s behavior in our cell system differs from other published studies (Bertolaso et al., 1998; Neri et al., 1999; Umar et al., 2000). In these studies aPKC resides in the cytosol in unstimulated cells and enters the nucleus after stimulation (Bertolaso et al., 1998; Neri et al., 1999; Umar et al., 2000), whereas in our system aPKC resides in the nucleus and exits to the cytosol and cell cortex after EGF stimulation. It should be noted that the cell lines and stimuli used in the various studies differ from each other and that the extent of stimulation in most studies was much longer than the few minutes that we applied in our studies.

aPKC Phosphorylates NMHC II-B Directly and Specifically
Our results have so far confirmed that NMHC II-B, PAK1, and aPKC form a complex in vivo and that the interaction between NMHC II-B and aPKC is EGF-dependent. Furthermore, the complex PAK1–aPKC, which is immunoprecipitated from cells, phosphorylates NMHC II-B in an EGF-dependent manner (Figure 1A and Even-Faitelson et al., 2005). Although PAK1 and aPKC are involved in NMHC II-B phosphorylation, the data above reveals that PAK1 does not phosphorylate NMHC II-B directly (Figure 1B). The next step, therefore, was to explore the possibility that aPKC phosphorylates NMHC II-B. We first examined whether the aPKC immunoprecipitated from TSU-pr1 cells is capable of phosphorylating the NMHC II-B tail, with IP-PAK1 used for comparison. As shown in Figure 4A, IP-aPKC phosphorylated the NMHC II-B tail to the same extent as IP-PAK1. These results suggest that the myosin heavy chain kinase (MHCK) activity detected in IP-PAK1 represents aPKC activity.

View larger version (38K): [in this window] [in a new window]   Figure 4. aPKC phosphorylates NMHC II-B directly in vitro and in vivo. (A) NMHC II-B tail phosphorylated by PAK1 or aPKC immunoprecipitated from TSU-pr1 cells (IP-PAK1 and IP-aPKC, respectively). As a negative control, the NMHC II-B tail was subjected to phosphorylation assay in the absence of IP-PAK1 or IP-aPKC (Tail only). The results are an average of two experiments ± SD. (B) NMHC II-A and NMHC II-B tail fragments were subjected to phosphorylation assay in the presence (+) or absence (–) of recombinant aPKC or MHCK preparation (Straussman et al., 2001; Ben-Ya’acov and Ravid, 2003). The tail fragments were resolved on SDS-PAGE and stained with Coomassie brilliant blue followed by an autoradiogram. The results are representative of five experiments. (C) GFP-NMHC II-B full-length or GFP alone were expressed in COS-7 cells, immunoprecipitated using GFP antibodies and subjected to phosphorylation assay in the presence or absence of aPKC. The top panels show the phosphorylated proteins (IP-GFP-NMHC II-B or IP-GFP) detected by an autoradiogram (Autoradiography), and the bottom panels show the total proteins as seen in Coomassie blue staining (Coomassie). (D) A representative Western blot analysis of the aPKC protein level after transfection of TSU-pr1 cells with aPKC siRNA (aPKC) or control siRNA (Control). Cells were transfected with the siRNA 48 h before the experiment. Ten percent of the lysates were subjected to Western blot analysis using aPKC antibody followed by p42-MAPK antibody, as a loading control. (E) A representative in vivo phosphorylation experiment of NMHC II-B in cells treated with aPKC siRNA. NMHC II-B was immunoprecipitated from cell lysates transfected as described in D. The immunoprecipitates were separated on SDS-PAGE and then stained with Coomassie blue (Coomassie). The gel was scanned, dried, and exposed to film (Autoradiography). (F) A plot representing the amount of phosphorylated NMHC II-B in cells treated with aPKC siRNA relative to the amount of phosphorylated NMHC II-B in the control cells. The amount of phosphorylated NMHC II-B was calculated by dividing the value of the phosphorylated NMHC II-B band by the value of the total NMHC II-B band from the gel. The plot summarizes results of three experiments such as the one described in E.

Because in vitro phosphorylation of a small part of a molecule may be nonspecific, we wanted to confirm that aPKC is capable of phosphorylating the full-length NMHC II-B. To examine whether aPKC is capable of phosphorylating full-length NMHC II-B, we expressed GFP-NMHC II-B in COS-7 cells, immunoprecipitated the molecule using GFP antibodies, and subjected it to an in vitro phosphorylation assay using recombinant aPKC, as described above. As shown in Figure 4C, aPKC was able to phosphorylate the full-length NMHC II-B, as in the case of NMHC II-B tail. A negative control in which we performed the same phosphorylation reaction, but in the absence of recombinant aPKC, confirms that the phosphorylation of NMHC II-B was carried out by aPKC and not by an unknown enzyme that may have coimmunoprecipitated with the GFP-NMHC II-B. Furthermore, when GFP alone was expressed, immunoprecipitated, and subjected to the same phosphorylation assay, it was not phosphorylated by aPKC (Figure 4C), thereby confirming that the phosphorylation on GFP-NMHC II-B is on the NMHC II-B region of the fusion protein and not on the GFP.

aPKC Phosphorylates NMHC II-B In Vivo
Because in vitro phosphorylation assays may result in nonspecific phosphorylation of substrates, it was essential to study whether aPKC also phosphorylates NMHC II-B in vivo. For this purpose, we performed siRNA experiments in which the expression of aPKC in TSU-pr1 cells was decreased. These cells were labeled with ³²P-orthophosphate and the phosphorylation level of the endogenous NMHC II-B after 1 min of EGF stimulation was determined. The siRNA treatment led to an average decrease of 50% in the protein level of aPKC (Figure 4D). As can be seen in Figure 4, E and F, the decrease in aPKC level led to a decrease of 25% in NMHC II-B phosphorylation level in vivo. The relatively small decrease in the phosphorylation level of NMHC II-B may be due to the partial decrease in aPKC expression and the phosphorylation of NMHC II-B by other kinases. It is known that NMHC II-B is phosphorylated by kinases other than aPKC, such as CKII and cPKC (Murakami et al., 1998; Rosenberg and Ravid, 2006). These kinases have 10 potential phosphorylation sites and therefore it is likely that they contribute to the observed phosphorylation. It should be noted that the same experiments were also carried out in cells that were not stimulated with EGF, and in those cells we also observed a decrease in NMHC II-B phosphorylation, but to a lesser extent. This result may imply that aPKC is also involved in NMHC II-B basal phosphorylation.

aPKC Phosphorylates a Specific Serine Residue Located on the Nonhelically Coiled Coil Tail of Myosin II-B
Our results strongly suggest that aPKC phosphorylates NMHC II-B directly and in a specific manner. The next step was to map the specific amino acid(s) in the NMHC II-B tail that undergo(es) phosphorylation by aPKC. First, we determined the enzyme-substrate ratio (i.e., aPKC -NMHC II-B tail) giving maximal incorporation of phosphate into the substrate. To do this, we performed phosphorylation assays and calculated the amount of phosphate incorporated into the NMHC II-B tail (described in Materials and Methods). The optimal ratio was 1:6.8 moles (aPKC -NMHC II-B tail) and 1.48 ± 0.307 mol phosphates were incorporated per mol NMHC II-B tail. In a control experiment in which aPKC was omitted from the reaction mixture, the amount of phosphate incorporated into NMHC II-B was 0.007 ± 0.004 mol phosphate per mol NMHC II-B tail (for details see Materials and Methods). There are thus probably one or two sites of phosphorylation for aPKC on NMHC II-B tail.

To map the phosphorylation site, we performed mass spectrometry analysis on phosphorylated NMHC II-B tail in comparison to native NMHC II-B tail, as described in Materials and Methods. The phosphorylated peak was identified by comparing the spectra of the phosphorylated NMHC II-B tail to that of the native protein. MS/MS was performed on the dissimilar peaks of the two samples and then on the phosphorylated peak, which was identified at 615.8 M/z. The mass spectrometry analysis showed that aPKC phosphorylates the NMHC II-B tail on a serine residue at position 1937 (Ser¹⁹³⁷) of the whole NMHC II-B protein (Figure 5A). This serine residue is located within a cluster of serine residues that reside in the nonhelical tailpiece (Figure 5B). This cluster of serine residues was previously suggested as a potential phosphorylation sites for PKC (Murakami et al., 1998, 2000), but it should be pointed out that the PKC preparation used in Murakami et al.’s (1998, 2000) study was purified from rat brains and contained a mixture of kinases, mainly , , and isoforms of PKC.

View larger version (12K): [in this window] [in a new window]   Figure 5. aPKC phosphorylates NMHC II-B tail on a serine residue on the nonhelical coiled coil C-terminus of myosin II-B. (A) Schematic representation of a myosin II-B molecule: a hexamer including two heavy chains and two pairs of light chains. The boxed area represents the region on the nonhelical tailpiece to which the aPKC phosphorylation site was mapped. (B) An enlargement of the boxed area in A, including the amino acid sequence surrounding the aPKC phosphorylation site. P (bold) represents the proline that breaks the -helical coiled coil of the molecule. S (gray) represents the Ser1937 residue, which is the aPKC phosphorylation site mapped by mass spectrometry.

aPKC Phosphorylates NMHC II-B In Vivo in Response to EGF Stimulation

View larger version (29K): [in this window] [in a new window]   Figure 6. aPKC phosphorylates NMHC II-B on Ser1937 in vivo in response to EGF stimulation. (A) Amino acid sequence of Tail-7A construct. P (bold) represents the proline that breaks the -helical coiled coil of the molecule. A (bold italic) represent the PKC phosphorylation sites that were replaced with alanines. A (bold, italic, and underlined) represents the mapped aPKC phosphorylation site that was replaced with an alanine residue in the Tail-7A construct (this residue was not replaced in Tail-6A construct). Asterisk (*) marks the putative CKII phosphorylation sites (Murakami et al., 1998). The bold italic A marked by an asterisk represents a serine residue replaced with alanine, which was mapped as a CKII phosphorylation site by Murakami et al. (1998) and as a PKC phosphorylation site by our lab (Rosenberg and Ravid, 2006). (B) In vivo phosphorylation of TailB-6A and TailB-7A. The fragments were expressed in TSU-pr1 cells, and their phosphorylation was examined in the presence or absence of a cell-permeable aPKC-specific inhibitor and with or without EGF stimulation. The bottom row shows the total protein, as seen in Coomassie staining; the row above that shows the phosphorylated proteins as seen in an autoradiogram. (C) The percent of Tail-6A and Tail-7A phosphorylation with or without EGF stimulation, after treatment with aPKC inhibitor. For each NMHC II-B fragment, the extent of phosphorylation in the presence of the inhibitor was compared with the extent of phosphorylation without inhibitor. The results are an average of three independent experiments ± SD. (D) The extent of phosphorylation of Tail-6A after 1 min after EGF stimulation relative to the extent of phosphorylation of Tail-6A from unstimulated cells. The graph represents the average relative phosphorylation of three separate experiments ± SD. The insets are a representative experiment, the top row shows the phosphorylated Tail-6A detected by an autoradiogram and the bottom row shows the total protein as seen in Coomassie staining.

These results correlate with the results described in Figure 2B, which show that coimmunoprecipitation of NMHC II-B with aPKC is EGF-dependent and that the maximum amount of NMHC II-B that coimmunoprecipitates with aPKC is 1 min after EGF stimulation. Moreover, Figure 3 shows that only 1 min after EGF stimulation, when aPKC translocates from the nucleus to the cytoplasm, there are areas where NMHC II-B and aPKC colocalize. Taken together, these results suggest that 1 min after EGF stimulation, aPKC translocates from the nucleus to the cytoplasm and phosphorylates NMHC II-B on Ser¹⁹³⁷. The small decrease in the phosphorylation of the two fragments in the presence of the inhibitor in unstimulated cells (Figure 6C) may reflect an indirect involvement of aPKC in the basal phosphorylation of NMHC II-B on sites other than the mutated ones, such as the CKII sites, which were left intact.

A Mutation Mimicking Phosphorylation on an aPKC’s Phosphorylation Site Leads to Slower Filament Assembly of Myosin II-B
Although it is well accepted that filament assembly of vertebrate nonmuscle myosin II is regulated by phosphorylation of the light chains, there is increasing evidence that phosphorylation of the C-terminal nonhelical tailpiece also plays a role in filament assembly (Tashiro et al., 1985; Hodge et al., 1992; Murakami et al., 1995, 1998, 2000). Moreover, Murakami et al. (2000) have shown that assembly is affected by mutations mimicking phosphorylation on a serine cluster located on myosin II-B nonhelical tailpiece. However, none of these studies have shown whether assembly of myosin II-B is affected by phosphorylation on the single serine residue, which we mapped to be a phosphorylation site of aPKC on NMHC II-B. To address this issue, we first compared the critical concentration needed for filament assembly of an NMHC II-B fragment (NMHC II-B rod) in comparison with a mutant NMHC II-B rod in which the aPKC phosphorylation site was changed to aspartate (S1937D), as described in Materials and Methods. It should be noted that we recently found that the solubility characteristics of NMHC II-B rod are similar to those of the whole myosin II-B molecule (Straussman et al., personal communication). We found that higher concentrations of protein are needed for the mutant S1937D rod to assemble into filaments. We tested this by dialyzing the proteins for 4 h against 150 mM NaCl and then centrifuging them at 100,000 x g. The wild-type NMHC II-B rod sediments almost entirely at a concentration of 15 and 25 µg/ml (only 6% of the protein is soluble), but a considerable amount of the S1937D rod was soluble at 15 or 25 µg/ml (39% or 31%, respectively). These results indicate that the S1937D mutation does change the assembly properties of the NMHC II-B rod.

We next determined whether the S1937D mutation changes the assembly kinetics of NMHC II-B rod. We again dialyzed the proteins against 150 mM NaCl, but this time we took out samples 1, 1.5, 2, 3, and 4 h after dialysis (as described in Materials and Methods). At these time points the osmolarity of the protein samples had reached the osmolarity of the dialysis solution (unpublished data). We next centrifuged the samples at 100,000 x g and separated the supernatant, containing soluble NMHC II-B rod, from the pellet, containing NMHC II-B rod that had assembled into filaments (Figure 7A).

View larger version (42K): [in this window] [in a new window]   Figure 7. A mutation mimicking phosphorylation on the aPKC phosphorylation site leads to slower filament assembly. (A) A representative Coomassie-stained SDS-PAGE of a solubility assay of NMHC II-B rod wild type (WT) and mutant, in which the aPKC phosphorylation site was changed to aspartate (S1937D). The proteins were dialyzed in 150 mM NaCl buffer for 1, 2, 3, or 4 h, and after centrifugation the supernatant (soluble NMHC II-B rod) and pellet (filamentous NMHC II-B rod) were separated on SDS-PAGE. (B) A plot of the relative amount of soluble NMHC II-B rod WT or S1937D mutant after 1, 1.5, 2, 3, and 4 h of dialysis in 150 mM NaCl buffer. Relative amount of soluble protein was calculated by dividing the amount of protein in the supernatant by the sum of the total protein in the supernatant and pellet fractions. The graph represents results from three independent experiments such as those described in A.

These results show that a single mutation mimicking phosphorylation on Ser¹⁹³⁷ on NMHC II-B, which is the phosphorylation site of aPKC, alters the filament assembly properties of myosin II-B. The S1937D mutation increases the critical concentration of the protein and slows down filament assembly. On the whole, these results imply that phosphorylation of aPKC on myosin II-B disrupts filament assembly.

PAK1 Is Involved in the Phosphorylation of aPKC
As PAK1 and aPKC reside in one complex, PAK1 may be able to phosphorylate aPKC directly. To test whether this is indeed the case, we expressed aPKC^WT fused to hemagglutinin (HA) in HEK-293 cells and then immunoprecipitated it with anti-HA antibodies as described in Materials and Methods. We subjected the immunoprecipitate to in vitro kinase assay in the presence or absence of recombinant GST-PAK1. As shown in Figure 8, aPKC^WT is phosphorylated to a much greater extent in the presence of GST-PAK1. The weak phosphorylation of aPKC^WT seen in the absence of GST-PAK1 can probably be accounted for by the autophosphorylation undergone by many PKCs (Newton and Koshland, 1987; Newton, 1997; Ron and Kazanietz, 1999). To check this, we expressed a kinase-dead mutant of aPKC (aPKC^KD) and subjected it to the same kinase assay. As shown in Figure 8, aPKC^KD was phosphorylated only in the presence of GST-PAK1, indicating that the phosphorylation seen on aPKC^WT in the absence of GST-PAK1 is indeed due to autophosphorylation and that GST-PAK1 phosphorylates aPKC directly.

View larger version (27K): [in this window] [in a new window]   Figure 8. PAK1 can phosphorylate aPKC in vitro. HA-aPKC wild-type (lanes 1 and 2), HA-aPKC kinase dead (lanes 3 and 4), or a GFP control (lanes 5 and 6) were transfected to HEK-293 cells and immunoprecipitated. The immunoprecipitate was subjected to an in vitro kinase assay in the presence (lanes 1, 3, and 5) or absence (lanes 2, 4, and 6) of recombinant GST-PAK1. The proteins were then separated on SDS-PAGE, stained with Coomassie brilliant blue (bottom panel), and exposed to autoradiography (top panel). The results are representative of three separate experiments.

View larger version (25K): [in this window] [in a new window]   Figure 9. PAK1 is involved in aPKC phosphorylation in vivo. (A) A representative Western blot showing PAK1 protein level after transfection of TSU-pr1 cells with PAK1 siRNA (PAK1) or fluorescein-conjugated control siRNA (Control). Cells were transfected with the siRNA 48 h before the experiment. To determine the expression level of PAK1 in siRNA cells, 10% of the lysates were subjected to Western blot analysis using PAK1 antibody followed by p42-MAPK antibody, as a loading control. (B) A representative in vivo phosphorylation experiment of aPKC. aPKC was immunoprecipitated from cell lysates transfected as described in A. The immunoprecipitates were separated on SDS-PAGE, which was then stained with silver stain. The gel was scanned, dried, and exposed to film (Autoradiography). (C) A plot representing the amount of phosphorylated aPKC in cells treated with PAK1 siRNA relative to the amount of phosphorylated aPKC in the control cells. The amount of phosphorylated aPKC was calculated by dividing the value of the phosphorylated aPKC band by the value of the total aPKC band from the gel. The plot summarizes results of three experiments such as the one described in B.

A Decrease in aPKC’s Expression Alters NMHC II-B Cellular Organization
We next wanted to see whether aPKC indeed plays a role in NMHC II-B regulation after EGF stimulation in vivo. To study the effect of aPKC on the cellular localization and organization of NMHC II-B upon EGF stimulation, we reduced the expression of aPKC in the cells using siRNA. These cells were stimulated with EGF for 1 min and subjected to indirect immunofluorescent staining using specific antibodies directed against aPKC and NMHC II-B as described in Materials and Methods. The micrographs in Figure 10A clearly demonstrate that lower levels of aPKC expression in the cells correlate with diffused appearance of NMHC II-B localization in those cells. It is also noticeable that in the same field of cells that were treated with aPKC siRNA there are also cells that show a higher level of expression of aPKC (